1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

  • January 2014
  • 130 pages
  • Visiongain
Report ID: 2041937

Summary

Table of Contents

Please note: The license is valid for 12 months from the date the report is sent.


Report Details

Uncommon nerve disorders - new study explains technological and commercial prospects

What's the future of medicines for rare central nervous system (CNS) disorders? Visiongain's new report gives you predictions for those therapies. Stay ahead. There you explore sales results, technologies, R&D trends, opportunities, and revenue forecasts.

So see what's possible for treating unusual neurological conditions. Avoid missing out. You gain data and financial analysis for that industry and market, appraising its outlooks. Find technological progress and commercial prospects, seeing potential gains.

Read on to explore those treatments and find what their future could be worth.

Forecasts and other analyses for therapy of rare (orphan) neurodegenerative disorders

Our new study reveals sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides forecasting revenues to 2024, that work shows historical results, growth rates, and market shares. There you get feel for technologies, regulatory outlooks, and developments (R&D). You also gain 41 tables, 40 charts, and two interviews with the industry.

Knowledge to help your work and save time, helping your influence

Our report strives to help your business research, analyses, and decisions on treatments for debilitating CNS diseases. There also see how you can save time. And find how you could benefit your authority through better understanding the present and future.

So the following sections explain what you get in that new investigation.

Forecasting of that world market and its main segments - you explore possibilities

What're the secrets of that industry's progress? What's its potential? Discover in our work overall world revenue to 2024 for orphan-drug CNS therapy.

Also in that report you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:
- Huntington's disease (HD)
- Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease, motor neurone disease)
- Myasthenia gravis (MG)
- Other treatment applications.

How will those categories expand? Which classes of therapy can generate most money? So you assess outlooks for sales growth, seeing where you can gain.

There you explore competition and rising sales for treating the rarer abnormalities causing neurodegeneration, autoimmune neuromuscular disorder, and other nerve disease.

You also assess top products' futures.

Predictions of leading agents' revenues

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for four marketed drugs:
- Xenazine (tetrabenazine)
- Rilutek (riluzole)
- Mestinon (pyridostigmine)
- Imuran (azathioprine).

There you find products and years with highest predicted sales and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and potentials.

Our study also divides its overall prediction into geographical regions.

Healthcare in leading national markets - what outlooks for those CNS drug sales?

In developed and developing countries, opportunities for providers of orphan neurological medicines will increase from 2014 to 2024. See where and how, finding sales potentials.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
- United States (US)
- Japan
- EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
- BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential sales growth. Our work explains. You assess needs and demands for those specialist medicines.

Explore, too, how that neur

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Clinical Chemistry Reagents and Analyzers Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 75000
  • Industry report
  • May 2017
  • by Venture Planning Group

This new 74-country report from VPGMarketResearch.com is available by region, country, market segment, section, or individual test. Please contact Client Services at reports@vpgcorp.com or +1 212 564 ...

Immunodiagnostics Analyzers and Reagents Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 75000
  • Industry report
  • July 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

Cancer Diagnostics Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Emerging Tumor Markers, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 52400
  • Industry report
  • May 2017
  • by Venture Planning Group

This new 74-country report from VPGMarketResearch.com is available by region, country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.